New Horizons in HER2+ Breast Cancer: Pharmacist-Focused Strategies and Insights |
|
- ACPE Pharmacy
- Participation
|
|
$0.00 |
Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo. |
Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy |
|
- ACPE Pharmacy
- Participation
|
|
$0.00 |
Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc. |
Pharmacist Perspectives: Exploring the Evolving Role of BTK Inhibitors in CLL |
|
- ACPE Pharmacy
- Participation
|
|
$0.00 |
Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored. |
Managing Cardiovascular Disease in the Time of COVID-19 |
|
- AMA PRA Category 1 Credit™
- Participation
|
|
$0.00 |
As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that cardiologists, who are tasked with managing a patient population with chronic cardiovascular disease (CVD) that is, resultantly, at high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to maintain effective CVD disease management while also keeping their patients safe. |
Oncology Clinical Briefing: Expert Insights for Managing Bladder Cancer in the Time of COVID-19 |
|
- AMA PRA Category 1 Credit™
- Participation
|
|
$0.00 |
As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients. |
Oncology Clinical Briefing: Expert Insights for Managing Breast Cancer in the Time of COVID-19 |
|
- AMA PRA Category 1 Credit™
- Participation
|
|
$0.00 |
As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients. |
Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition |
|
|
|
$0.00 |
Click here to complete this activity |
Anticoagulation Reversal for Life-threatening Bleeding: A Case-based Presentation for the Critical Care Team |
|
|
|
$0.00 |
Click here to complete this activity |
New Treatments for Rare Mutations in NSCLC |
|
- AMA PRA Category 1 Credit™
|
|
$0.00 |
|
Precision Therapy in NSCLC: Pharmacist Perspectives on Testing Strategies and Biomarker-Driven Treatment Approaches |
|
- ACPE Pharmacy
- Participation
|
|
$0.00 |
Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca. |